AbbVie Foe Coherus Sways PTAB To Review Humira Patent

The Patent Trial and Appeal Board of the US Patent & Trademark Office has agreed to hold a trial under its inter partes review process to consider the validity of one of AbbVie Inc.'s dosing methods patents. The challenger, Coherus BioSciences Inc., is hoping to eventually market a biosimilar of Humira in the US.